Galoretx Pharmaceuticals Private Limited, a active private limited company, was established on 12 July 2018 in Udupi, Karnataka, India. Engaging in biotechnology within the professional, scientific and technical sector, it holds CIN: U85320KA2018PTC114735. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹0.10 M.
Employing 10 professional, Its leadership includes Chenna Krishna Gundala (Director), Raghuveer Kallajhari Ramachandra (Whole-Time Director), Kallajhari Subrahmanya Ramachandra (Whole-Time Director). Past directors included Chenna Krishna Gundala, Raghuveer Kallajhari Ramachandra, Kallajhari Subrahmanya Ramachandra. It holds ₹1.80 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at #1-1-16(S)1 Kallajhari, Udupi, Karnataka, 576102.
U85320KA2018PTC114735
114735
12 July 2018
₹1.00 M
₹0.10 M
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Galoretx Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chenna Krishna Gundala | Director | 06 Feb 2023 | Current |
| Raghuveer Kallajhari Ramachandra | Whole-Time Director | 12 Jul 2018 | Current |
| Kallajhari Subrahmanya Ramachandra | Whole-Time Director | 12 Jul 2018 | Current |
| Sasikumar Govindannair Pottayil | Director | 06 Feb 2023 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 29 Sep 2023 | Past |
| Pramod Abcsdd | Director | 30 Dec 2019 | Past |
| Pramod Abcsdd | Director | 30 Dec 2019 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2023 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Galoretx Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 128.66% increase. The company also saw a substantial fall in profitability, with a 43.99% decrease in profit. The company's net worth moved up by a moderate rise of 2.77%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
Unlock access to Galoretx Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
₹18,017,991.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Feb 2025 | Others | ₹1.00 Cr | Open |
| 01 Aug 2024 | Others | ₹7.02 M | Open |
| 03 Oct 2022 | Others | ₹1.00 M | Open |
Explore comprehensive loan charge details -
Galoretx Pharmaceuticals has a workforce of 10 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Galoretx Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Galoretx Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge with Others amounted to Rs. 10.00 M with Charge ID 101063153 was registered on 25 Feb 2025. was completed.
Galoretx Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
A charge with Others amounted to Rs. 7.02 M with Charge ID 100965615 was registered on 01 Aug 2024. was recorded as a recent event.
Galoretx Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore. was recorded as a recent event.
The activity Chenna Krishna Gundala was appointed as a Director was appointed as a Director on 06 Feb 2023 & has been associated with this company since 2 years 9 months . was completed.
Progress on Sasikumar Govindannair Pottayil was appointed as a Director was appointed as a Director on 06 Feb 2023 & has been associated with this company since 2 years 9 months . was documented.
The CIN of Galoretx Pharmaceuticals Private Limited is U85320KA2018PTC114735.
Galoretx Pharmaceuticals Private Limited is headquartered at #1-1-16(S)1 Kallajhari, Udupi, Karnataka, 576102.
Galoretx Pharmaceuticals Private Limited was incorporated on 12 July 2018.
The current directors of Galoretx Pharmaceuticals Private Limited are
The primary industry of Galoretx Pharmaceuticals Private Limited is Professional, Scientific And Technical.
Galoretx Pharmaceuticals Private Limited is unlisted.
The authorized capital of Galoretx Pharmaceuticals Private Limited is ₹1.00 M, and the paid-up capital is ₹0.10 M.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX